ProfoundBio has raised $70 million to advance two of its oncology drug candidates into clinical trial. The company is developing antibody-drug conjugates, which target cells with an antibody and deliver… Read More
ProfoundBio, based in Woodinville, Wash., and Suzhou, China, has raised $55 million in a Series A funding round to advance its programs developing new anti-cancer agents. The company is led… Read More